Bicosome has developed a technology that allows to bring a cosmetic or pharmaceutical active ingredient to the appropriate skin layer to optimize its effect; a product that begins to take its place in the healthcare capital with the help of ACCIÓ’s Road to Boston program.
“In the cosmetic area, we have been operating in the United States since 2014 in a growing business,” explains Lucyanna Barbosa, CEO of the company. However, Bicosome wanted to go further and also operate in the field of health. “We also see a lot of potential in chronic skin diseases. We are doing a project in the pharma and medical device area; and that’s why we were interested in the Road to Boston “, explains the motivation to sign up for this program. One of these projects is the collaboration with the North American company Dermalytica, fruit of the meetings held in Boston during the participation in the program. “In fact, the collaboration with Bicosome will allow Dermalytica to develop with more guarantees your project, submitted to the SBIR.
According to Barbosa, the main advantage is “the time saving that it takes you to have someone there who knows the market and understands your project. He can introduce you, introduce you to the right people and guide you on who you should talk to. It opens many doors for you. “One door, the one in Boston, that has to allow Bicosome to move towards an ambitious goal:” to separate into two business units: cosmetics and pharma, with different business models “.
